世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000037765

抗肥満薬市場-規模、シェア、動向分析レポート、およびセグメント予測、2024〜2030

Grand View Research Inc.

Anti-obesity Medication Market Size, Share & Trends Analysis Report, And Segment Forecasts, 2024- 2030

発刊日 2024/03

言語英語

体裁PDF/110ページ

ライセンス/価格110ページ

0000037765

Individual
Team
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

抗肥満薬の市場規模、シェア、動向分析レポート:製品別 (承認済み、適応外)、作用機序別 (末梢作用型薬、中枢作用型薬)、流通チャネル別、地域別、セグメント別予測、2024〜2030

抗肥満薬の市場規模と動向

世界の抗肥満薬の市場規模は、2023年に66億2,000万ドルと推定され、2024年から2030年にかけて31.66%のCAGRで成長すると予測されます。世界的に肥満が増加しており、効果的な治療法に対する需要が高まっています。糖尿病や心血管疾患など、太りすぎに関連する健康への影響に対する意識の高まりが、この市場の需要増大に寄与すると予想されます。多額の研究開発投資に支えられた抗肥満薬の開発の加速が、市場の成長を後押しするでしょう。医薬品開発技術の進歩により、市場はさらなる成長が見込まれており、太りすぎに関連する健康上の課題と戦うという差し迫ったニーズに対応しています。

レポート詳細

目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Mechanism of Action
1.2.3. Distribution Channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Mechanism of Action outlook
2.2.3. Distribution Channel outlook
2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. Anti-Obesity Medication Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing Prevalence of Obesity-Related Conditions
3.2.1.2. Government Regulations and Guidelines
3.2.1.3. Increase in technological advancements
3.2.2. Market restraint analysis
3.2.2.1. Side Effects and Adverse Reactions
3.2.2.2. High cost of anti-obesity drugs
3.3. Anti-Obesity Medication Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape

Chapter 4. Anti-Obesity Medication Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Anti-Obesity Medication Market by Product Outlook
4.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Approved
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1. Bupropion-naltrexone (Contrave)
4.4.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Liraglutide (Saxenda)
4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Orlistat
4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3.2. Xenical
4.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3.3. Alli
4.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Phentermine-topiramate (Qsymia)
4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.5. Semaglutide (Wegovy)
4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.6. Setmelanotide (Imcivree)
4.4.1.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.7. Tirzepatide (Zepbound)
4.4.1.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Off Label
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.1.1. Semaglutide (Ozempic)
4.4.2.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.1.2. Liraglutide (Victoza)
4.4.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.1.3. Dulaglutide (Trulicity)
4.4.2.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.1.4. Topiramate (Dulaglutide (Trulicity))
4.4.2.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.1.5. Other
4.4.2.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Anti-Obesity Medication Market: Mechanism of Action Estimates & TrendAnalysis
5.1. Segment Dashboard
5.2. Global Anti-Obesity Medication Market Movement Analysis
5.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Mechanism of Action, 2018 to 2030 (USD Million)
5.4. Peripherally Acting Drugs
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Centrally Acting Drugs
5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Anti-Obesity Medication Market: Distribution Channel Estimates & Tren Analysis
6.1. Segment Dashboard
6.2. Global Anti-Obesity Medication Market Movement Analysis
6.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Retail Pharmacies
6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Hospital Pharmacies
6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Others
6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Anti-Obesity Medication Market: Regional Estimates & Trend Analysis
7.1. Regional Market Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Mexico
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. Argentina
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Novo Nordisk A/S
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. GSK plc
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Novartis AG
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. VIVUS LLC
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Currax Pharmaceuticals LLC
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Boehringer Ingelheim International GmbH
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Rhythm Pharmaceuticals, Inc.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Gelesis
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives

List of Tables
Table 1 List of key distributors and channel partners
Table 2 List of key emerging companies’/technology disruptors/innovators
Table 3 North America Anti-Obesity Medication Market, by country, 2018 - 2030 (USD Million)
Table 4 North America Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 5 North America Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 6 North America Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 7 U.S. Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 8 U.S. Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 9 U.S. Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 10 Canada Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 11 Canada Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 12 Canada Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 13 Europe Anti-Obesity Medication Market, by country, 2018 - 2030 (USD Million)
Table 14 Europe Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 15 Europe Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 16 Europe Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 17 Germany Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 18 Germany Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 19 Germany Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 20 UK Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 21 UK Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 22 UK Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 23 France Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 24 France Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 25 France Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 26 Italy Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 27 Italy Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 28 Italy Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 29 Spain Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 30 Spain Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 31 Spain Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 32 Denmark Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 33 Denmark Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 34 Denmark Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 35 Sweden Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 36 Sweden Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 37 Sweden Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 38 Norway Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 39 Norway Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 40 Norway Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Anti-Obesity Medication Market, by country, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 44 Asia Pacific Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 45 Japan Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 46 Japan Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 47 Japan Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 48 China Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 49 China Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 50 China Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 51 India Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 52 India Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 53 India Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 54 Australia Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 55 Australia Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 56 Australia Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 57 South Korea Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 58 South Korea Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 59 South Korea Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 60 Thailand Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 61 Thailand Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 62 Thailand Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 63 Latin America Anti-Obesity Medication Market, by country, 2018 - 2030 (USD Million)
Table 64 Latin America Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 65 Latin America Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 66 Latin America Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 67 Brazil Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 68 Brazil Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 69 Brazil Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 70 Mexico Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 71 Mexico Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 72 Mexico Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 73 Argentina Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 74 Argentina Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 75 Argentina Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 76 MEA Anti-Obesity Medication Market, by country, 2018 - 2030 (USD Million)
Table 77 MEA Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 78 MEA Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 79 MEA Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 80 South Africa Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 81 South Africa Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 82 South Africa Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 85 Saudi Arabia Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 86 UAE Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 87 UAE Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 88 UAE Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 89 Kuwait Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 90 Kuwait Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 91 Kuwait Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Anti-Obesity Medication Market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain - based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Anti-Obesity Medication Market snapshot (2023)
Fig. 9 Anti-Obesity Medication Market: Segment snapshot (2023)
Fig. 10 Competitive Insights (2023)
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Anti-Obesity Medication Market driver impact
Fig. 15 Anti-Obesity Medication Market restraint impact
Fig. 16 Clinical chemistry industry challenges
Fig. 17 Porter’s Five Forces Analysis
Fig. 18 SWOT Analysis, By Factor (Political & legal Economic and technological)
Fig. 19 Strategic alliance analysis
Fig. 20 Recent developments & impact analysis, by key market participants
Fig. 21 Key company market share analysis, 2023
Fig. 22 Company market position analysis
Fig. 23 Definition and scope, by product
Fig. 24 Product market share analysis, 2023 & 2030
Fig. 25 Segment dashboard
Fig. 26 Global Anti-Obesity Medication Market, by product, 2018 - 2030 (USD Million)
Fig. 27 Approved market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 28 Bupropion - naltrexone (Contrave) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 29 Liraglutide (Orlistat) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 30 Orlistat market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 31 Xenical market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 32 Alli market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 33 Phentermine - topiramate (Qsymia) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 34 Semaglutide (Wegovy) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 35 Tirzepatide (Zepbound) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 36 Setmelanotide (Imcivree) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 37 Off Label market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 38 Semaglutide (Ozempic) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 39 Liraglutide (Victoza) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 40 Dulaglutide (Trulicity) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 41 Topiramate (Dulaglutide (Trulicity)) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 42 Others market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 43 Definition and scope, by Distribution Channel
Fig. 44 Distribution Channel market share analysis, 2023 & 2030
Fig. 45 Segment dashboard
Fig. 46 Global Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Fig. 47 Retail Pharmacies market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 48 Hospital Pharmacies market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 49 Others market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 50 North America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 51 U.S. market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 52 Canada market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 53 Europe market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 54 UK market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 55 Germany market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 56 Spain market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 57 France market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 58 Italy market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 59 Sweden market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 60 Denmark market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 61 Norway market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 62 Asia Pacific market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 63 China market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 64 Japan market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 65 India market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 66 Australia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 67 South Korea market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 68 Thailand market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 69 Latin America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 70 Brazil market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 71 Mexico market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 72 Argentina market size, & forecasts and trend analysis, 2018 to 2030 (USD Million))
Fig. 73 Middle East and Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 74 South Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 75 Saudi Arabia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 76 UAE market size, & forecasts and trend analysis, 2018 to 2030(USD Million)
Fig. 77 Kuwait market size, & forecasts and trend analysis, 2018 to 2030(USD Million)

この商品のレポートナンバー

0000037765

TOP